Acumen Pharmaceuticals press release (ABOS): Q3 GAAP EPS of -$0.35 beats by $0.02. – Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027
Acumen Pharmaceuticals GAAP EPS of -$0.35 Beats by $0.02
Acumen Pharmaceuticals press release (ABOS): Q3 GAAP EPS of -$0.35 beats by $0.02. - Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027